Flair also analysed dozens of open letters published by alumnae of private schools who complained last year about racist abuse they had endured in schools and a lack of black role models among teachers.

Nicholas Hewlett, head of St Dunstan's College private school in southeast London, said staff were worried by a 'righteous generation' of children who were looking for their teachers to 'trip up' on even 'small, persistent slights'.

In the UK, the pandemic and a crackdown on immigration following Brexit contributed to unpredictable supplies of fruits, vegetables and prepared foods in stores and restaurant chains, said Shane Brennan, chief executive at the Cold Chain Federation.

Selpercatinib is the first drug from Loxo's pipeline that Lilly has brought to market.
Prior to the acquisition, Loxo won approval of Vitrakvi, which targets a different genetic mutation and is sold by Bayer AG.

Flair also analysed dozens of open letters published by alumnae of private schools who complained last year about racist abuse they had endured in schools and a lack of black role models among teachers.

Nicholas Hewlett, head of St Dunstan's College private school in southeast London, said staff were worried by a 'righteous generation' of children who were looking for their teachers to 'trip up' on even 'small, persistent slights'.

"I encourage parents of teens in all states to talk to their teens and discourage them from sexting because even when sexting is consensual, those images are out of the control of the teens as soon as they have sent them," Davis said.

Nicholas Hewlett, head of St Dunstan's College private school in southeast London, said staff were worried by a 'righteous generation' of children who were looking for their teachers to 'trip up' on even 'small, persistent slights'.

Although the company will continue to pursue "higher-risk, high reward" drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky.

Although the company will continue to pursue "higher-risk, high reward" drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky.